Roswell Park Comprehensive Cancer Center will open a $98 million cell and gene therapy manufacturing facility. It will be the first cell and gene therapy hub in New York.
A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase I clinical trial for patients with triple-negative breast cancer, the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer.
